Integra LifeSciences Holdings Corp. is fleshing out its regenerative products business and accelerating its move into the diabetic foot ulcer market with the $312 million all-cash acquisition of TEI Biosciences Inc. and TEI Medical Inc.
Privately-held TEI, based in Waltham, Mass., specializes in regenerative wound care and soft tissue repair. It generated revenue of $63.5...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?